Cerca Articoli

Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Resp

Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells.Sabrina Rotolo 1, Simona Ceccarelli 1, Ferdinando Romano 1, Luigi Frati 1,2, Cinzia Marchese 1, Antonio Angeloni 1* 1 Dipartimento di Medicina Sperimentale, Universita` Sapienza di Roma, Roma, Italy, 2 Istituto Neurologico Mediterraneo ‘‘Neuromed, Pozzilli, ItalyAbstract : BackgroundKeratinocyte growth factor receptor (KGFR) is a splice variant of the FGFR2 gene expressed in epithelial cells. Activation of KGFR is a key factor in the regulation of physiological processes in epithelial cells such as proliferation, differentiation and wound healing. Alterations of KGFR signaling have been linked to the pathogenesis of different epithelial tumors. It has been also hypothesized that its specific ligand, KGF, might contribute to the development of resistance to 5-fluorouracil (5-FU) in epithelial cancers and tamoxifen in estrogen-positive breast cancers.Abstract : Methodology/Principal FindingsSmall interfering RNA was transfected into a human keratinocyte cell line (HaCaT), a breast cancer derived cell line (MCF-7) and a keratinocyte primary culture (KCs) to induce selective downregulation of KGFR expression. A strong and highly specific reduction of KGFR expression was observed at both RNA (reduction = 75.7%, P = 0.009) and protein level. KGFR silenced cells showed a reduced responsiveness to KGF treatment as assessed by measuring proliferation rate (14.2% versus 39.0% of the control cells, P

The Book of Games: V. 1

Di Bendik Stang

USA CREATES UNIFIED COMMAND POST IN AFRICA

Suicide bombing near hotel kills six Iraqis

Army official: Security staff 'prevented a greater loss of life'

Red Cross cuts Iraq operations

The International Committee of the Red Cross is cutting back its operations in Iraq after warnings that it could be targeted for attack.

THE FANCONI ANAEMIA/BRCA PATHWAY

Fanconi anaemia (FA) is a rare genetic cancer-susceptibility syndrome that is characterized by congenital abnormalities, bone-marrow failure and cellular sensitivity to DNA crosslinking agents. Seven FA-associated genes have recently been cloned, and their products were found to interact with well-known DNA-damage-response proteins, including BRCA1, ATM and NBS1. The FA proteins could therefore be involved in the cell-cycle checkpoint and DNA-repair pathways. Recent studies implicate the FA proteins in the process of repairing chromosome defects that occur during homologous recombination, and disruption of the FA genes results in chromosome instability ”€ a common feature of many human cancers.